These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23179163)

  • 1. Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information.
    Mohseninejad L; Feenstra T; van der Horst HE; Woutersen-Koch H; Buskens E
    Eur J Health Econ; 2013 Dec; 14(6):947-57. PubMed ID: 23179163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis.
    Spiegel BM; DeRosa VP; Gralnek IM; Wang V; Dulai GS
    Gastroenterology; 2004 Jun; 126(7):1721-32. PubMed ID: 15188167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
    Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
    Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis.
    Mein SM; Ladabaum U
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1199-210. PubMed ID: 15153173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remarkable prevalence of coeliac disease in patients with irritable bowel syndrome plus fibromyalgia in comparison with those with isolated irritable bowel syndrome: a case-finding study.
    Rodrigo L; Blanco I; Bobes J; de Serres FJ
    Arthritis Res Ther; 2013; 15(6):R201. PubMed ID: 24283458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of celiac disease and related antibodies in patients diagnosed with irritable bowel syndrome according to the Rome III criteria. A case-control study.
    Sánchez-Vargas LA; Thomas-Dupont P; Torres-Aguilera M; Azamar-Jacome AA; Ramírez-Ceervanes KL; Aedo-Garcés MR; Meixueiro-Daza A; Roesch-Dietlen F; Grube-Pagola P; Vivanco-Cid H; Remes-Troche JM
    Neurogastroenterol Motil; 2016 Jul; 28(7):994-1000. PubMed ID: 26914655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers.
    Almario CV; Noah BD; Jusufagic A; Lew D; Spiegel BMR
    Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1434-1441.e21. PubMed ID: 29596984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
    Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
    J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undiagnosed Celiac Disease In Patients Presenting With Irritable Bowel Syndrome Symptoms.
    Khayyat YM
    J Ayub Med Coll Abbottabad; 2020; 32(1):18-23. PubMed ID: 32468748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls.
    Cash BD; Rubenstein JH; Young PE; Gentry A; Nojkov B; Lee D; Andrews AH; Dobhan R; Chey WD
    Gastroenterology; 2011 Oct; 141(4):1187-93. PubMed ID: 21762658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
    Arrospide A; Rue M; van Ravesteyn NT; Comas M; Soto-Gordoa M; Sarriugarte G; Mar J
    BMC Cancer; 2016 Jun; 16():344. PubMed ID: 27251556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.
    Shah ED; Saini SD; Chey WD
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2687-2695.e11. PubMed ID: 30831219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis.
    Irvine AJ; Chey WD; Ford AC
    Am J Gastroenterol; 2017 Jan; 112(1):65-76. PubMed ID: 27753436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coeliac disease in irritable bowel syndrome (Rome III) in Southeast Iran.
    Bakhshipour A; Nezam SK; Zakeri Z; Gharibi R; Bahari A; Kaykhaei MA
    Arab J Gastroenterol; 2012 Mar; 13(1):24-7. PubMed ID: 22560821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care.
    Stamuli E; Bloor K; MacPherson H; Tilbrook H; Stuardi T; Brabyn S; Torgerson D
    BMC Gastroenterol; 2012 Oct; 12():149. PubMed ID: 23095351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland.
    Fisher M; Walker A; Falqués M; Moya M; Rance M; Taylor D; Lindner L
    Eur J Health Econ; 2016 Dec; 17(9):1091-1100. PubMed ID: 26728984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
    Karnon J; Czoski-Murray C; Smith K; Brand C; Chakravarthy U; Davis S; Bansback N; Beverley C; Bird A; Harding S; Chisholm I; Yang YC
    Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
    van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
    Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celiac Disease in Patients Fulfilling the Rome III Criteria for Irritable Bowel Syndrome Attending Gastroenterology Department of A Tertiary Care Hospital in Bangladesh.
    Chowdhury MK; Chakraborty R; Gope S; Rahman MA; Miah AR; Raihan AS; Sarkar S; Paul BK; Ferdousi KR
    Mymensingh Med J; 2016 Jan; 25(1):102-8. PubMed ID: 26931258
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.